Insulet price target raised to $355 from $320 at UBS

UBS analyst Danielle Antalffy raised the firm’s price target on Insulet (PODD) to $355 from $320 and keeps a Neutral rating on the shares. Broad-based strength and record new patients prompted an increase in Insulet’s outlook, the analyst tells investors in a research note.